| abstract |
This invention relates to a novel process for producing a new proline derivative of immunomycin (FK-520), designated "prolyl-immunomycin" that has immunosuppressant activity. This process involves directed biosynthesis, a fermentation process in which a cultured Streptomyces organism, e.g. Streptomyces hygroscopicus subsp. ascomyceticus, ATCC 55087, is grown in the presence of proline or its salts as biosynthetic precursors. |